ISH plays a crucial role in personalized cancer therapy by identifying specific genetic alterations that can be targeted with tailored treatments. For instance, detecting HER2 gene amplification in breast cancer through ISH can determine the eligibility for targeted therapies like trastuzumab. Similarly, identifying ALK rearrangements in lung cancer can guide the use of ALK inhibitors.
